Licensing Opportunities

The La Jolla Institute for Immunology is a world-renowned research organization specializing in human immunology and its role in human disease. Our 20+ principal investigators conduct groundbreaking, world changing research in all areas of immunology including oncology, cardiovascular disease, infectious diseases, allergy, inflammation, and autoimmunity. A number of their pioneering innovations are in clinical development. In addition, LJI is a leader in the worldwide effort for identification and bioinformatic characterization of antigens, including management of the Immune Epitope Database and the development of peptide pools used to diagnose viral infections and characterize immune response.

LJI and its researchers partner with companies in a variety of capacities, including as scientific advisors, through sponsored research collaborations and by licensing technologies. There are over 300 technologies available for licensing, some of which are listed below. LJI welcomes inquiries regarding licensing and other collaborative opportunities. Please contact us at bd@lji.org to get in touch with our business development group. We look forward to making introductions to investigators and exploring how we can work together.

Technology Spotlight

3-mer

Researchers at the La Jolla Institute for Immunology (LJI) and Louisiana State University Health Shreveport (LSUHS) have discovered a novel human cytomegalovirus (HCMV) protein complex that they believe facilitates cell-to-cell spread of HCMV in cell types key for virus-induced disease. This complex is composed of three known HCMV proteins that were not known to bind together and be incorporated into the virion envelope, and thus is termed the “3-mer.”

HRF inhibitors

Researchers at the La Jolla Institute for Immunology (LJI) have developed rabbit monoclonal antibodies that recognize the HRF N19 peptide and are working to humanize these antibodies for therapeutic use. These mAbs were generated by screening a phage antibody library, and they inhibited IgE binding of HRF in vitro and in ovalbumin-induced food allergy in vivo.

HVEM Muteins

Researchers at the La Jolla Institute for Immunology and the Albert Einstein College of Medicine together have generated HVEM mutants that selectively recognize either the TNF ligand LIGHT or the Ig ligands BTLA and CD160 in vitro. Knock-in mice expressing these muteins maintain expression of all the proteins in the HVEM network yet demonstrate selective functions for LIGHT or BTLA/CD160.

Monkeypox Epitopes

Researchers in the Sette lab at the La Jolla Institute for Immunology (LJI) have compiled known epitope information to determine protein conservation and immunodominance for both CD4+ and CD8+ T cell responses to Monkeypox virus (MPXV). Additionally, the researchers have developed epitope pools that can be utilized to assess responses to vaccination and MPXV infection.

VFLIP

Researchers in the Saphire lab have developed a novel pre-fusion stabilized SARS-CoV-2 Spike (S) glycoprotein termed “VFLIP” for (V) five proline, Flexibly-Linked, Inter-Protomer spike.